Ocugen, Inc. (OCGN) stock
OCGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.83−0.05 (-5.24%)
Close on Nov 13, 2026Market cap $280.72MP/E –Yield –
Earnings
Ocugen's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 3, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$1.95M
+11.4% on a year earlier
EPS, Q3 FY2026
-$0.01
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Ocugen's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 3, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 4, 2026before the open | $1.95M | +11.4% | -$0.01 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026before the open | $1.49M | +8.4% | -$0.07 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 4, 2026after the close | – | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 4, 2026during market hours | -$193.00K | -125.3% | -$0.06 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 5, 2025before the open | $1.75M | +54.2% | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 1, 2025during market hours | $1.37M | +20.3% | -$0.05 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 9, 2025during market hours | $1.48M | +46.1% | -$0.05 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 5, 2025before the open | $764.00K | – | -$0.05 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 8, 2024during market hours | $1.14M | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024during market hours | $1.14M | – | -$0.04 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 14, 2024during market hours | $1.01M | – | -$0.05 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 9, 2023before the open | – | – | -$0.06 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 21, 2023after the close | – | – | -$0.10 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 5, 2023before the open | – | – | -$0.07 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 28, 2023before the open | – | – | -$0.10 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 8, 2022before the open | – | – | -$0.10 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 5, 2022before the open | – | – | -$0.09 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 6, 2022before the open | – | – | -$0.09 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 25, 2022before the open | – | – | -$0.07 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 9, 2021before the open | – | – | -$0.05 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 6, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 7, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 18, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 20, 2020before the open | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Jul 16, 2020before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Ocugen has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Ocugen puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Ocugen filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Results
- Update
- Update
- Update
- Results
- Results
- News
- Update
- Results
- Results
- Results
- Results
- Results
See a number that looks wrong?